Day Traders, Penny Stocks, Stock Options, Futures and Forex

Ingen Introduces Oxyview Products at ATS
Effective Advertising and Product Branding Scheduled for 2010


Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.0023 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Thursday January 14, 2010, 8:15 am

YUCAIPA, Calif., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced the introduction of their Oxyview product line at the 2010 ATS International Conference on May 14-19, 2010 in New Orleans, Louisiana.



The American Thoracic Society (ATS) is committed to disseminating the latest advances, nationally and internationally, in the fields of lung disease, sleep disorders and critical care medicine. The annual International Conference has become the premier, international forum for physicians and scientists who work in pulmonary, critical care, and sleep medicine.



The company will reach 13,000 pulmonologists through the advertising in Medco Forum's ATS issue that is scheduled to be released on May 1, 2010. Medco Forum will also host the Oxyview advertising on their website.



The company now advertises in several major publications, inclusive of COPD Digest, Today's Senior Magazine and Medco Forum.



Throughout 2009, Ingen showcased their newest medical respiratory equipment at several conventions, including the MEDICA convention in Germany and the American Association of Respiratory Care (AARC) in San Antonio, Texas. These showings captured the attention of many distributors who were interested in Oxyview, taking Ingen a step closer to achieving international distribution and a growing presence in the hospital and therapy markets.



As the number of respiratory diseases continue to increase, so too does the number of patients requiring oxygen support. That's why Ingen expects to see more demand for the Oxyview Nasal Cannula and the Oxyview Pulse Oximeter in 2010 and the coming years. The company expects to acquire more distributors in the United States and the developing markets of Asia, Canada, Australia and Europe.



ATS 2010 * New Orleans



Medco Forum



Ingen Technologies,Inc. - Home



About Ingen:



Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters

IGNT Off to a slow start this morning. Stock is bearish right now but with this news that came out on the stock this morning I expect this stock to bounce back this afternoon and tmw. I also think today the stock will push through .25 and .26 today and see more apprecation tmw. I personally am playing this as a swing trade. Remember to do ur own research and this is strictly my opinion

2010 Looks to be a Big Year for Ingen Technologies
The Company Expects More Distributors, in the U.S. and Abroad, to Pick Up Oxyview

.Companies:Ingen Technologies, Inc..Press Release Source: Ingen Technologies, Inc. On Thursday January 14, 2010, 2:00 pm

YUCAIPA, Calif., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced that they will engage Medical Strategies International (MSI) to increase sales of the Oxyview product line through GPO contracts.



MSI specializes in helping companies increase sales through Group Purchasing Organizations (GPOs), Integrated Delivery Networks (IDNs), and Equipment Planners. Medical Strategies International (MSI) is a strategic business-consulting firm focused on the Medical industry. MSI's Executive Team is highly trained healthcare professionals with over 70 years experience in the Sales, Marketing, Government and Corporate Account Management of medical products and services. Our goal is to assist companies that manufacture or distribute products and services to the Hospital/Physician market and help them increase sales through the extremely important arena of Healthcare Group Purchasing Organizations and Integrated Health Delivery Networks.



In the United States, a healthcare group purchasing organization (or GPO) is an entity that is created to leverage the purchasing power of a group of hospitals to obtain discounts from vendors based on the collective buying power of the GPO members. Group purchasing is used in many industries to purchase raw materials and supplies, but it is common practice in the health care industry.



The Oxyview Nasal Cannula has garnered a lot of attention at several conventions throughout the world. This showing captured the attention of many distributors who are interested in this new medical technology, opening the doors to the possibility that Oxyview will become available worldwide to patients outside of the United States by March of 2010. Ingen recently unveiled its latest in medical respiratory equipment; the new Oxyview Pulse Oximeter.



In 2010, the adult nasal cannula manufacturer plans to aggressively market its medical devices to hospitals. But Ingen's bold plans for growth don't end here. The company also hopes to work with distributors to make the Oxyview product line available worldwide beginning in March-2010. Recently, at the MEDICA convention in Germany, Ingen's showcase of Oxyview earned the company attention from multiple distributors that were on hand for the event.



"We look forward to working with Ken Kuiper of Medical Strategies International. Our plan is to capture the VA Hospital market with our expected GSA approval, and capture the commercial hospital market through GPO contracts. The Oxyview Nasal Cannula and the Oxyview Pulse Oximeter will be a great improvement to oxygen therapy in the hospital setting," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Ingen CEO Interview on The Money Channel
Increase Sales of the Oxyview Product Line Through GPO Contracts


Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.0020 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Friday January 15, 2010, 7:15 am

YUCAIPA, Calif., Jan. 15, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced that they will engage Medical Strategies International (MSI) to increase sales of the Oxyview product line through GPO contracts. The company points to the increasing prevalence of respiratory diseases, emerging hospital markets, and developing world markets. The CEO will discuss this with host Steve Crowley today at 9:34AM eastern standard time on the world renowned Money Channel's American Scene Radio.



The company projects that the Oxyview Nasal Cannula will bring $10M in revenues, and the new Oxyview Pulse Oximeter an additional $1M in revenues in 2010.



The Money Channel // American Scene Radio // WallStreetCast



Ingen Technologies,Inc. - Home



About Ingen:



Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Ignt a strong buy today. News came out this morning. Keep this stock on your radar list. I am currently going to take a position with a few other investors on this company. A good time to buy this stock while the price is low. I expect this stock to break through the 20 day ma of .0021 and bounce hold at the 50 day ma of .0026. good luck to you all!!

IGNT closed @ .002 looking to break next resistance of .0021 (50 day MA). Over the last two weeks of trading, IGNT HOD has reached anywhere between .023-.032; hopefully we continue to see this trend to see some price appriciation.

Related Quotes
Symbol Price Change
IGNT.PK 0.0018 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Wednesday January 20, 2010, 8:15 am EST

YUCAIPA, Calif., Jan. 20, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced that the current quarter sales represented an increase of 17.7% from sales in the quarter ended November 30, 2008. Sales were sparked by the introduction of Oxyview Nasal Cannula unit that includes a cannula with Ingen’s Oxyview unit. Additional capital also enabled the company to increase the advertising and marketing of the Oxyview products. Ingen anticipates that the sales of Oxyview will increase from the current quarter’s sales as the Company expands its sales channels.



The total cost of sales for the quarter ended November 30, 2009 has a gross margin of 90.8%. The reported cost of sales for the quarter ended November 30, 2008 had a gross margin of 89.4%. The Company anticipates that its gross margin will continue to stay in the range of the current quarter.



The largest components of Ingen’s SG&A are advertising, legal and professional services, travel associated with both sales and business development, outside services and salaries. The advertising expense increased from zero in the quarter ended November 30, 2008 to $41,090 in the quarter ended November 30, 2009. The Company expects to continue advertising at current levels as it continues to promote Oxyview.



The Company has reduced its debt to the note holders by $2.3M, and expects to reduce the entire balance by March-2010. The company anticipates a share buy-back program for all of its shareholders once the note is paid in full.



The company projects that the Oxyview Nasal Cannula will bring $10M in revenues, and the new Oxyview Pulse Oximeter an additional $1M in revenues in 2010.



Ingen Technologies,Inc. - Home


About Ingen:



Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

Ingen Takes Final Steps Towards Increased Export Sales
ISO Auditor Approves Stage-I for Ingen


Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.0016 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Tuesday February 9, 2010, 8:15 am EST

YUCAIPA, Calif., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced today that the company was granted approval of the Stage-I audit conducted by BSI America, Inc. on February 5, 2010.



On February 5, 2010 the company was audited by Mr. Brian Nguyen, one of the certified auditors with BSI America, Inc. According to Mr. Nguyen, Ingen's management system documentation meets the requirements of the ISO 13485:2003, the MDD 93/42/EEC Annex V (M5), and the CMDR. The internal audits and management review processes are being planned and performed. Based on the objective evidences noted from the areas assessed during this Stage-I audit, it is recommended that Ingen proceed to the final Stage-II audit. There were no outstanding non-conformities to review from previous assessments. No new non-conformities were identified during the assessment.



Ingen Technologies is strongly committed to the success of this company and continues driving forward in a direction that is within the best interest of its shareholders. The company has pending back-orders for export sales to China, Japan, Canada, Europe and Australia. Ingen has seen an increase in the value with its intellectual property, research & development, new medical product lines, inventory and other assets, while revenues show a steady incline. ISO Certification is expected to result in a large revenue jump of the company's respiratory product lines.



BSI: Standards, Training, Testing, Assessment & Certification


FDA Consultants, US FDA Regulatory Consulting


Ingen Technologies,Inc. - Home


About Ingen:



Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.


Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Want the latest penny stock news? Stock picks are on fire in this site and was acknowledged by experts. With an average of 299% gaining success.

#1 Newsletter

An informative newsletter of 2010... try it!


Click here ----- Trusted Stock Picks